Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

CRESCENDO Investigators, Eric J Topol, Marie-Germaine Bousser, Keith A A Fox, Mark A Creager, Jean-Pierre Despres, J Donald Easton, Christian W Hamm, Gilles Montalescot, P Gabriel Steg, Thomas A Pearson, Eric Cohen, Christophe Gaudin, Bernard Job, Judith H Murphy, Deepak L Bhatt

Research output: Contribution to journalArticlepeer-review

Abstract

Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.
Original languageEnglish
Pages (from-to)517-23
Number of pages7
JournalThe Lancet
Volume376
Issue number9740
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this